Eurepa (Repaglinide) 0.5mg – 100 tablet

USD $63.92

Each Eurepa contains .5 mg Repaglinide 100 tablets. Used to treat diabetic adults who suffer from Diabetes Mellitus type 2 diabetes.

ATC Classification: A10BX02
Active Ingrediant: Repaglinide
Generic Name: Eurepa
Manufacturer: Torrent
Strength: 0.5mg
Dosage Type: Tablet
Packaging Type: Foil in Box
Contains: 30 TABLET

Examples of Packages sent

Use

Diabetes mellitus, type 2:?To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise

 

Medication Safety Issues

Sound-alike/look-alike issues:

Prandin may be confused with Avandia

Repaglinide may be confused with rasagiline

 

Storage/Stability

Store at 20?C to 25?C (68?F to 77?F). Protect from moisture.

 

Adverse Reactions

>10%:

Central nervous system: Headache (9% to 11%)

Endocrine & metabolic: Hypoglycemia (16% to 31%)

Respiratory: Upper respiratory tract infection (10% to 16%)

1% to 10%:

Cardiovascular: Ischemia (4%), chest pain (2% to 3%)

Gastrointestinal: Diarrhea (4% to 5%), constipation (2% to 3%)

Genitourinary: Urinary tract infection (2% to 3%)

Hypersensitivity: Hypersensitivity reaction (1% to 2%)

Neuromuscular & skeletal: Back pain (5% to 6%), arthralgia (3% to 6%)

Respiratory: Sinusitis (3% to 6%), bronchitis (2% to 6%)

<1%, postmarketing, and/or case reports: Alopecia, anaphylactoid reaction, blurred vision (transient), cardiac arrhythmia, ECG abnormality, hemolytic anemia, hepatic insufficiency (severe), hepatitis, hypertension, increased liver enzymes, jaundice, leukopenia, myocardial infarction, palpitations, pancreatitis, Stevens-Johnson syndrome, thrombocytopenia, visual disturbance (transient)

Additional information

Active Ingrediant

Generic Name

Alternate Names

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Strength

Dosage Type

Packaging Type

Brand

Torrent Pharma

Reviews

There are no reviews yet.

Be the first to review “Eurepa (Repaglinide) 0.5mg – 100 tablet”

Your email address will not be published. Required fields are marked *